PSYB:CC News and Press, Psybio Therapeutics Corp. From 01/05/23

Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 5, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being d...

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT Canada NewsWire PsyBio continues to demonstrate its ...

PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio Canada NewsWire PsyBio continues to increase its presence in the psycho-targeted biosynthesis intellectual property space and remains strongly committ...

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing Canada NewsWire /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED S...

PsyBio Therapeutics Reports Third Quarter 2022 Financial Results Canada NewsWire OXFORD, Ohio and DENVER , Nov. 29, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio " or the " Company "), a fully integrated...

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial Canada NewsWire PsyBio continues towards understanding psycho-targeted, biosynthesized tryptamines and remains strongly committed to innovation, development, and technology optimization ...

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted Canada NewsWire PsyBio continues to increase its presence in the psycho-targeted biosynthesis intellectual property space and remains strongly committed to innovation, development, and te...

PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022 Canada NewsWire OXFORD, Ohio and DENVER, Colo. , Sept. 7, 2022 /CNW/ - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF)  (" PsyBio " or the " Company "...

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application Canada NewsWire Biosynthetic Production covers Methylated Tryptamine Derivatives including DMT and 5-MeO-DMT ...

PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications Canada NewsWire PsyBio is continuing to increase its psycho-targeted patent portfolio, executing on its strategic priorities of innovation, development, and technolog...